Methods and models to evaluate shear-dependent and surface reactivity-dependent antithrombotic efficacy

Thrombosis Research

Volumn 104, Issue 3, 2001, Pages 149-174

  Sakariassen, Kjell S ^a,b,e   Hanson, Stephen R ^c   Cadroy, Yves ^d  

^a PFIZER INC   (United States)

^b Pharmacia Corporation   (Sweden)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CHU PURPAN   (France)

^e Merck Serono SpA   (Italy)

Author keywords

Antithrombotics; Coagulation; Platelets; Shear; Surface reactivity; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7A; CLOPIDOGREL; CYCLOOXYGENASE 1 INHIBITOR; FIBRINOGEN RECEPTOR; FLUINDIONE; HEPARIN; HIRUDIN; IODIXANOL; IOHEXOL; IOXAGLIC ACID; LINOTROBAN; LIPOCORTIN 5; LOW MOLECULAR WEIGHT HEPARIN; OMEGA 3 FATTY ACID; RETINOIC ACID; THROMBIN INHIBITOR; THROMBOCYTE RECEPTOR; THROMBOPLASTIN; THROMBOXANE A2; TICLOPIDINE; TISSUE FACTOR PATHWAY INHIBITOR; VON WILLEBRAND FACTOR; WARFARIN;

ANTICOAGULATION; ARTICLE; BLOOD FLOW; CIRCULATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG INHIBITION; DRUG SCREENING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MEASUREMENT; NONHUMAN; PRIORITY JOURNAL; SHEAR RATE; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE MEMBRANE; THROMBOGENESIS; THROMBOSIS;

EID: 0035499651     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(01)00344-9     Document Type: Review

References (170)

1. Blood viscosity, mass transport, and thrombogenesis
2. Rheological aspects of thrombosis and hemostasis: Basic principles and applications
3. Adhesion of platelets to subendothelium
4. Subendothelial proteins and platelet adhesion: Von Willebrand factor and fibronectin, not thrombospondin, are involved in platelet adhesion to extracellular matrix of human vascular endothelial cells
5. Ex vivo models for studying thrombosis: Special emphasis on shear rate dependent blood-collagen interactions
6. Effect of blood flow on thrombin formation: Influence of the nature procoagulant and non-procoagulant surfaces
7. Tissue factor-induced coagulation triggers platelet thrombus formation as efficiently a fibrillar collagen at arterial blood flow conditions
8. Tissue factor predicts the thrombogenicity of human atherosclerotic plaque components
9. Initial deposition of platelets and fibrin on vascular surfaces in flowing blood
10. The unstable atherosclerotic plaque: Clinical significance and therapeutic intervention
11. Blood flow and antithrombotic drug effects
12. Correction of FVIII of the impaired platelet adhesion to subendothelium in von Willebrand's disease
13. Effect of shear on platelet interaction with subendothelium in citrated and native blood. Shear-rate dependent decrease of adhesion in von Willebrand's disease and the Bernard-Soulier syndrome
14. Human blood platelet adhesion to artery subendothelium is mediated by factor VIII-von Willebrand factor bound to the subendothelium
15. Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia
16. Deficiency of platelet membrane glycoprotein Ia associated with decreased platelet adhesion to subendothelium: A defect in platelet spreading
17. Decreased adhesion of giant (Bernard-Soulier) platelets to subendothelium. Further implications on the role of the von Willebrand factor in hemostasis
18. Role of platelet membrane glycoproteins and von Willebrand factor in adhesion of platelets to subendothelium and collagen
19. The role of platelet glycoprotein Ib and IIb/IIIa in platelet adherence to human artery subendothelium
20. Platelet adhesion and thrombus formation on subendothelium in platelets deficient in glycoprotein IIb-IIIa and storage granules
21. Platelets lacking functional CD36 (glycoprotein IV) show reduced adhesion to collagen in flowing whole blood
22. Role of shear rate and platelets in promoting fibrin formation on rabbit subendothelium. Studies utilizing patients with quantitative and qualitative platelet defects
23. Scott syndrome: A disorder of platelet coagulant activity
24. Studies on the haemostatic defect in a complicated syndrome - An inverse Scott syndrome platelet membrane abnormality
25. Relationship between endothelial tissue factor and thrombogenesis under blood flow conditions
26. Fibrin formation, fibrinopeptide A release, and platelet thrombus dimensions on subendothelium exposed to flowing native blood: Greater in factor XII and XI than in factor VIII and IX deficiency
27. Regulation of platelet-fibrin thrombi on subendothelium
28. Fibrinogen-independent platelet adhesion and thrombus formation on subendothelium mediated by glycoprotein IIb-IIIa complex at high shear rate
29. Reduced thrombus formation in native blood of homozygous factor VII deficient patients at high arterial wall shear rate
30. Platelet interaction with rabbit subendothelium in von Willebrand's disease: Altered thrombus formation distinct from defective platelet adhesion
31. Shear rate dependent decrease of thrombus growth on collagen in non-anticoagulated blood from patients suffering from von Willebrand disease and hemophilia A
32. Antithrombotic effects of thrombin-induced activation of endogenous Protein C in primates
33. The thrombomodulin/protein C/protein S anticoagulant pathway modulates the thrombogenic properties of the normal and stimulated endothelium
34. Annexin V inhibits the procoagulant activity of TNF-stimulated endothelial cells under flow conditions
35. The vWf-binding domain of platelet membrane glycoprotein Ib
36. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa
37. Inhibition of fibrinogen binding to GPIIb-IIIa by a GPIIIa peptide
38. Pharmacological approaches to thrombin regulation
39. Anticoagulant activity of synthetic hirudin peptides
40. Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa
41. Isolation of antistasin. An inhibitor of metastasis and coagulation
42. Antithrombotic benefits and hemorrhagic risks of direct thrombin inhibitors
43. Peptide sequences from the EGF-2 like domain of FVII inhibit tissue factor dependent FX activation
44. HN-11500 - A novel thromboxane A2 receptor antagonist with antithrombotic activity in humans at arterial blood flow conditions
45. Clopidogrel - A platelet inhibitor which inhibits thrombogenesis in human non-anticoagulated blood independently of the blood flow conditions
46. Modulation of thrombotic responses in moderately stenosed arteries by cigarette smoking and aspirin ingestion
47. Studies of Suloctidil in experimental thrombosis in baboons
48. In vivo inhibition of acute platelet dependent thrombosis in a baboon model by Bay U3405, a thromboxane A2 receptor antagonist
49. Antihemostatic and antithrombotic effects of monoclonal antibodies against von Willebrand factor in non-human primates
50. Von Willebrand factor-mediated platelet adhesion to collagen involves platelet membrane glycoprotein IIb/IIIa as well as glycoprotein Ib
51. RGDV peptide selectivity inhibits platelet dependent thrombus formation in vivo
52. Modulation of procoagulant activity of extracellular endothelial matrix by anti-tissue factor antibody and the synthetic peptide arg-gly-asp-val. Experiments with flowing non-anticoagulated human blood
53. Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets
54. Antithrombotic efficacy of the vitamin K antagonist fluindione in a human ex vivo model of arterial thrombosis. Effect of anticoagulation level and combination therapy with aspirin
55. Discrimination between platelet-mediated and coagulation-mediated mechanisms in a model of complex thrombus formation in vivo
56. Relative antithrombotic effects of monoclonal antibodies targeting different platelet glycoprotein-adhesive molecule interactions in nonhuman primates
57. Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates
58. Optimal antagonism of GPIIb/IIIa favors platelet adhesion by inhibiting thrombus growth. An ex vivo capillary perfusion study in the guinea pig
59. Relative involvement of GPIb/IX-vWF axis and GPIIb/IIIa in thrombus growth at high shear rates in the guinea pig
60. Reduced effect of aspirin on thrombus formation at high shear and disturbed laminar blood flow
61. Inhibition of platelet-dependent thrombosis by low molecular weight heparin (CY222): Comparison with standard heparin
62. A comparative study of the anticoagulant and the antithrombotic effects of unfractionated heparin and a low molecular weight heparin (Fraxiparine) in an experimental human venous thrombosis model
63. Nonfractionated heparin fails to inhibit arterial thrombosis in a human ex vivo thrombosis model
64. Dermatan sulfate inhibition of fibrin-rich thrombus formation in nonhuman primates
65. Antithrombotic effects of synthetic pentasaccharide with high affinity for plasma antithrombin III in non-human primates
66. Active site-blocked factors VIIa and IXa differentially inhibit fibrin formation in a human ex vivo thrombosis model
67. Antithrombotic efficacy of inactivated active site recombinant factor VIIa is shear dependent in human blood
68. Recombinant leech antiplatelet protein prevents collagen-mediated platelet aggregation but not collagen graft thrombosis in baboons
69. Selective factor Xa inhibition by recombinant antistasin prevents vascular graft thrombosis in baboons
70. Antithrombotic efficacy of recombinant tick anticoagulant peptide. A potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis
71. Effect of selective factor Xa inhibition on arterial thrombus formation triggered by tissue factor/factor VIIa or collagen in an ex vivo model of human shear dependent thrombus formation
72. Endothelial stimulation with tumor necrosis factor-alpha express varying amounts of tissue factor resulting in inhomogeneous fibrin deposition in a native blood flow system. Effects of thrombin inhibitors
73. Thrombin plays a key role in late platelet thrombus growth and/or stability. Effect of a specific thrombin inhibitor on thrombogenesis induced by aortic subendothelium exposed to flowing rabbit blood
74. Thrombin regulation of platelet interaction with damaged vessel wall and isolated collagen type I at arterial flow conditions in a porcine model: Effects of hirudins, heparin and calcium chelation
75. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethylketone
76. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons
77. Antithrombotic effects of synthetic peptides targeting different functional domains of thrombin
78. Antithrombotic strategies targeting thrombin activities, thrombin receptors, and thrombin generation
79. Comparison of the antithrombotic effect of PEG-hirudin and heparin in a human ex vivo model of experimental arterial thrombosis
80. Tissue factor pathway inhibitor prevents thrombus formation on procoagulant subendothelial matrix
81. Retinoic acid reduces induction of monocyte tissue factor and tissue factor/factor VIIa-dependent arterial thrombus formation
82. No effect of daily dietary supplement of 24 g omega-3 fatty acids on acute platelet-dependent thrombus formation in flowing non-anticoagulated blood
83. Interruption of vascular thrombus formation and vascular lesion formation by dietary n-3 fatty acids in fish oil in nonhuman primates
84. A double-blind randomized comparison of combined aspirin and ticlopidine therapy versus aspirin and ticlopidine alone on experimental arterial thrombogenesis in humans
85. Early potential antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombosis in man
86. The antiaggregating and antithrombotic activity of ticlopidine is potentiated in the rat
87. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents
88. Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves
89. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement
90. Role of ADP and thromboxanes in thrombus formation in human ex vivo models
91. Impact of shear, collagen fibrils and tissue factor on anticoagulation and antiplatelet agents
92. Effect of aspirin and epinephrine on experimentally-induced thrombogenesis in dogs: A parallelism between in vivo and ex vivo thrombosis models
93. Analysis of shear stress and hemodynamic factors in a model of artery stenosis and thrombosis
94. Blood platelets are concentrated near the wall and red blood cells in the center of flowing blood
95. Collagen-induced thrombus formation at the apex of eccentric stenoses. A time course study with non-anticoagulated blood
96. Red blood cell size is important for adherence of blood platelets to artery subendothelium
97. Red blood cell deformability influences platelet-vessel wall interaction in flowing blood
98. A perfusion chamber developed to investigate thrombus formation and shear profiles in flowing native human blood at the apex of well-defined stenoses
99. Mechanisms of thrombus formation at arterial plaques
100. Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with severe stenosis
101. Shear-induced platelet activation and platelet microparticle formation in human native blood
102. The clinical value of tissue factor assays
103. Procoagulant human monocytes mediate tissue factor/factor VIIa dependent platelet-thrombus formation in flowing non-anticoagulated human blood
104. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque
105. Regulation of the procoagulant response to arterial injury
106. Pathophysiology implications of membrane phospholipid asymmetry in blood cells
107. Morphologic features of unstable atherothrombotic plaques underlying acute coronary syndromes
108. Thrombosis and coronary atherosclerosis
109. The epidemiology, pathogenesis, and natural history of venous thrombosis
110. Regulation of thrombin generation at cell surfaces
111. Collaborative overview of randomised trials of antiplatelet therapy: III. Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients
112. Inhibition of platelet adhesion to fibrino(gen) in flowing whole blood by Arg-Gly-Asp and fibrinogen gamma-chain carboxy terminal peptides
113. Glycoprotein Ib, von Willebrand factor, and glycoprotein IIb: IIIa are all involved in platelet adhesion to fibrin in flowing whole blood
114. Fibronectin in artery subendothelium is important for platelet adhesion
115. Platelet adhesion to laminin: Role of Ca2+ and Mg2+ ions, shear rate, and platelet membrane glycoproteins
116. Increased platelet deposition in atherosclerotic coronary arteries
117. Thrombus formation on ruptured atherosclerotic plaques and rethrombosis on evolving thrombi
118. Biochemistry, immunology, and cell biology of endothelium
119. Measurements of platelet interaction with components of the vessel wall in flowing blood
120. Activation of endothelial cells induces platelet thrombus formation on their matrix. Studies of new in vitro thrombosis model with low molecular weight heparin as anticoagulant
121. Influence of fibrillar collagen structure on the mechanisms of platelet thrombus formation under flow
122. The role of blood flow in platelet adhesion, fibrin deposition, and formation of mural thrombi
123. Effect of physical factors on platelet adherence to subendothelium
124. Platelet interaction with collagen fibrils in flowing blood: I. Reaction of human platelets with α-chymotrypsin-digested subendothelium
125. A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix and purified components
126. Collagen type III induced ex vivo thrombogenesis in humans: Role of platelets and leukocytes in deposition of fibrin
127. Comparison of platelet interaction with subendothelium of human renal and umbilical arteries and the extracellular matrix produced by human venous endothelial cells
128. Platelet-dependent primary hemostasis promotes selectin- and integrin-mediated neutrophil adhesion to damaged endothelium under flow conditions
129. Flow effects on prostacyclin production by cultured human endothelial cells
130. Platelet aggregation in flowing blood at a site of injury to an endothelial cell monolayer: Quantitation and real-time imaging with the TAB monoclonal antibody
131. Design and construction of a linear shear stress flow chamber
132. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor
133. A new perfusion chamber to detect platelet adhesion using a small volume of blood
134. Adhesion and aggregation: Morphological demonstration and quantitation in vivo and in vitro
135. Growth and stability of thrombi in flowing blood: Assessment of platelet-surface interactions with computer-assisted morphometry
136. Adhesion of blood platelets to the extracellular matrix of cultured human endothelial cells
137. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa
138. Axial dependence of platelet-collagen interactions in flowing blood: Upstream thrombus growth impairs downstream platelet adhesion
139. Upstream thrombus growth impairs downstream thrombogenesis in non-anticoagulated blood: Effect of procoagulant artery subendothelium and non-procoagulant collagen
140. Axial dependence of collagen-induced thrombus formation in flowing non-anticoagulant human blood: Anti-platelet drugs which impairs thrombus growth and increases platelet-collagen adhesion
141. Initial interactions of platelets and plasma proteins in flowing non-anticoagulated human blood with the artificial surfaces Dacron and Teflon (PTFE)
142. Factor VIII-von Willebrand factor requires calcium for facilitation of platelet adherence
143. Effects of acetylsalicylic acid, sulfinpyrazone and dipyridamole on platelet adhesion and aggregation in flowing native and anticoagulated blood
144. Platelet interaction with subendothelium in a perfusion system: Physical role of red blood cells
145. Effects of anticoagulation on the interaction of human platelets with subendothelium in flowing blood
146. Factors controlling thrombus formation on arterial lesions
147. Factors influencing the growth, stability, and fate of arterial thrombi
148. Immunologic quantification of fibrin deposition in thrombi formed in flowing native human blood
149. A new method for quantifying platelet deposition in flowing native blood in an ex vivo model of human thrombogenesis
150. Iohexol, platelet activation and thrombosis: I. Iohexol-induced platelet secretion does not affect thrombus formation in native blood
151. Iohexol, platelet activation and thrombosis: II. Iohexol-induced platelet secretion does not affect collagen-induced or tissue factor-induced thrombus formation in blood that is anticoagulated with heparin and aspirin
152. Platelet interactions with Dacron vascular grafts. A model of acute thrombosis in baboons
153. Discrimination between platelet-mediated and coagulation-mediated mechanisms in a model of complex thrombus formation in vivo
154. Characterization of a tubular flow chamber for studying platelet interaction with biological and prosthetic materials: Deposition of indium 111-labelled platelets on collagen, subendothelium and expanded polytetrafluorethylene
155. Platelet thrombus formation on collagen type I. A model of deep vessel wall injury Influence of blood rheology, von Willebrand factor, and blood coagulation
156. Influence of arterial damage and wall shear rate on platelet deposition. Ex vivo study in a swine model
157. Local delivery of antithrombin inhibits platelet-dependent thrombosis
158. In vivo evaluation of artificial surfaces using a nonhuman primate model of arterial thrombosis
159. Effects of platelet modifying drugs on arterial thromboembolism in baboons
160. Effects of red blood cell concentration on hemostasis and formation in a primate model
161. The role of high wall shear rate on thrombus formation in stenoses
162. Mechanisms of arterial thrombosis in nonparallel streamlines: Platelet thrombi grow on the apex of stenotic severely injured vessel wall
163. A four-hour infusion of recombinant hirudin results in long-term inhibition of arterial-type thrombosis in baboons
164. Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis
165. Inhibition of platelet dependent thrombus formation by human activated protein C
166. Thromboembolic potential of synthetic vascular grafts in baboon
167. An in-vitro model to study device-induced thrombosis and embolism: Evaluation of the efficacy of tirofiban, aspirin and dipyridamole
168. Protamine sulphate inhibits platelet membrane glycoprotein Ib-von Willebrand factor activity
169. Platelet adhesion to multimeric and dimeric von Willebrand factor and to collagen type III preincubated with von Willebrand factor